Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
Follow SNY
Sanofi (SNY) Beneish M-score
Sanofi's Beneish M-score for fiscal 2025 is −2.63; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.63 | 0.03 |
| FY2024 | −2.66 | (0.03) |
| FY2023 | −2.63 | (0.05) |
| FY2022 | −2.59 | (0.11) |
| FY2021 | −2.48 | (0.23) |
| FY2020 | −2.24 | 0.45 |
| FY2019 | −2.70 | (0.18) |
| FY2018 | −2.52 | 0.11 |
| FY2017 | −2.63 | 0.03 |
| FY2016 | −2.66 | 0.16 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.99 | — | 0.91 | |
| Gross margin index | 0.97 | — | 0.51 | |
| Asset quality index | 1.12 | — | 0.45 | |
| Sales growth index | 1.10 | — | 0.98 | |
| Depreciation index | 0.73 | — | 0.08 | |
| SG&A index | 0.99 | — | −0.17 | |
| Total accruals to total assets | (0.05) | — | −0.21 | |
| Leverage index | 1.09 | — | −0.36 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.63 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| BMY Bristol Myers Squibb Company compare | −2.7× |
| SNY Sanofi | −2.6× |
| PFE Pfizer Inc. compare | −2.5× |
| AZN AstraZeneca PLC compare | −2.5× |
| NVO Novo Nordisk A/S compare | −2.5× |
| NVS Novartis AG compare | −2.5× |
| GSK GSK PLC Sponsored ADR compare | −2.5× |
| GILD Gilead Sciences, Inc. compare | −2.5× |
| AMGN Amgen Inc. compare | −2.3× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI